https://www.selleckchem.com/pr....oducts/merbarone.htm
In this article, we present the pivotal abstracts presented at the 'AACR Virtual Meeting COVID-19 and Cancer' held in July 2020. Much is unknown regarding the effect of COVID-19 on cancer patients, and this conference presented important updates in therapeutics and epidemiology. Specifically, cancer therapeutics have been hypothesized to treat cytokine release syndrome in patients with COVID-19, and the JAK1/2 inhibitor, ruxolitinib, is currently being used in a Phase III trial to assess its efficacy. Additionally, similar to other st
Like
Comment
Share
